

UPDATE OF THE EARLY DEMAND MAP FOR THE PUBLIC INNOVATION PURCHASE OF THE MedeA PROJECT (PUBLISHED IN APRIL 2019).

NOTE: Corresponds to Former Challenge 5 on the Initial Early Demand Map (April 2019).

CHALLENGE 4: DEVELOPMENT OF SYSTEMS FOR THE ASSESSMENT OF ADVERSE DRUG REACTIONS		[SeRAM]
NEED	DESCRIPTION	PROCEDURE TO FOLLOW
<p>It is required to develop evaluation of pharmacological effects in patients in their daily life (specifically Adverse Drug Reactions-RAMs-), to complete the needs that the project aims to solve, linked to the development of a PoPS integrated with the EHR, which integrates genetic data and other determinants of interindividual variability in response to drugs.</p> <p>One of the most important needs in health care processes is to improve and reinforce communication between professionals and patients. The professionals must gather information from the patients in order to know their symptoms, ailments, personal and mental situation and, on the other hand, it is necessary to provide the patients with information about their situation, the activities and care acts, their diagnosis, treatment, self-care recommendations, habits, etc., in an understandable way, so that they can act accordingly.</p> <p>This aspect is therefore addressed through the development of tools for the remote evaluation of the efficacy/safety of the patient's treatments in everyday life conditions, thus allowing useful and accurate information to be added to the individualized pharmacological prescription process.</p>	<p>Development of methodology for clinical evaluation in regular conditions of daily life, specifically, as it refers to the efficacy/safety of pharmacological treatment (RAMs) in order to relate it to pharmacogenetic factors.</p> <ul style="list-style-type: none"> • This will require the development and application of sensorized and interactive tools/devices for the collection of adverse reaction data and individual patient clinical data, including pharmacogenetic information, with the aim of generating a Remote Efficacy/Safety Assessment System (SeRAM). • Through the development of sensorized and interactive tools/devices for the remote collection and analysis of physical and psychological parameters of patients, the aim is to develop and implement an individual clinical evaluation system, for which information from different (harmonized) sources about the state of health will be adapted, potentially with data collection from the clinical history of the patients, using it specifically for the evaluation of the efficacy/safety ratio of pharmacological treatment. <p>SeRAM Development</p> <p>Corresponds to Old Challenge 5 on the Initial Early Demand Map (April 2019).</p>	<p>Innovative Public Procurement / Innovation Partnership</p>

Available budget Challenge 4: **560.791**.

Maximum budget to be awarded per company in Phase I (VAT included): **373,860.48 €**.